MXD1 and triple-negative breast carcinoma: In our published work, we have established that the treatment of triple-negative breast cancer (TNBC) cell lines with SMI MS-905, which targets the interaction between the MAD1 (MXD1) and PAH2 domain of Sin3A, exhibits remarkable phenotypes both in vitro and in vivo [20].